Chemotherapy-induced Gut Toxicity and Pain: Involvement of TLRs

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2015 Nov 20

PMID 26581898

Citations 9

Authors

Rachel J Gibson

Janet K Coller

Hannah R Wardill

Mark R Hutchinson

Scott Smid

Joanne M Bowen

Affiliations

Soon will be listed here.

Abstract

Purpose: Chemotherapy-induced gut toxicity is associated with significant pain, and pain influences gut function. Toll-like receptors (TLRs) that regulate gut homeostasis are activated by tissue damage and microbes, and their altered expression following chemotherapy may change cellular responses. This study examined the interaction between chemotherapy-induced gut toxicity and pain and related these to gut TLR and glial fibrillary acidic protein (GFAP) expression.

Methods: Female tumor bearing Dark Agouti rats received irinotecan (175 mg/kg, n = 34) or vehicle (n = 5) and were assessed over 120 h for gut toxicity (diarrhea, weight loss), pain (facial), and GFAP, TLR2, 4, 5, and 9 gut expression.

Results: Irinotecan caused diarrhea (72 % of animals grade ≥ 1), weight loss (11.1 ± 6.6 %, P < 0.0001), and pain (5 (0-5), P < 0.0001) all peaking at 72 h. Higher pain scores were observed in rats with diarrhea versus those without: median (range) of 2.0 (0-5) versus 0 (0-5), P = 0.01. Irinotecan also caused a decrease in TLR4 and 5, and an increase in GFAP expression in jejuna crypt at 96 and 120 h (all P < 0.05); with lower TLR4 expression associated with lower pain (P = 0.012).

Conclusions: The association between gut toxicity and pain suggests these toxicities are linked, possibly via TLR-mediated inflammatory pathways. Further, as TLR4 and 5 expression was absent during recovery in the jejuna and GFAP expression was increased in the jejuna, this implies expression of these may be critical in the healing phase following chemotherapy. Detailed studies of gut TLRs and GFAP are now warranted.

Citing Articles

The Debate between the Human Microbiota and Immune System in Treating Aerodigestive and Digestive Tract Cancers: A Review.

Domingues C, Cabral C, Jarak I, Veiga F, Dourado M, Figueiras A Vaccines (Basel). 2023; 11(3).

PMID: 36992076 PMC: 10055943. DOI: 10.3390/vaccines11030492.

Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity.

Tam J, Crame E, Elz A, Coller J, Wignall A, Prestidge C Cancer Chemother Pharmacol. 2022; 90(3):267-278.

PMID: 35962138 PMC: 9402738. DOI: 10.1007/s00280-022-04463-x.

Chemotherapy induced gastrointestinal toxicities.

Akbarali H, Muchhala K, Jessup D, Cheatham S Adv Cancer Res. 2022; 155:131-166.

PMID: 35779873 PMC: 10033220. DOI: 10.1016/bs.acr.2022.02.007.

A Novel Strategy to Identify Haematology Patients at High Risk of Developing Aspergillosis.

Griffiths J, White P, Thompson A, da Fonseca D, Pickering R, Ingram W Front Immunol. 2022; 12():780160.

PMID: 34975870 PMC: 8716727. DOI: 10.3389/fimmu.2021.780160.

Chemotherapy-Induced Intestinal Microbiota Dysbiosis Impairs Mucosal Homeostasis by Modulating Toll-like Receptor Signaling Pathways.

Wei L, Wen X, Xian C Int J Mol Sci. 2021; 22(17).

PMID: 34502383 PMC: 8431669. DOI: 10.3390/ijms22179474.

References

Sonis S . Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol. 2007; 5(9 Suppl 4):3-11. View

Stringer A, Al-Dasooqi N, Bowen J, Tan T, Radzuan M, Logan R . Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer. 2013; 21(7):1843-52. DOI: 10.1007/s00520-013-1741-7. View

Carlotto A, Hogsett V, Maiorini E, Razulis J, Sonis S . The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. Pharmacoeconomics. 2013; 31(9):753-66. DOI: 10.1007/s40273-013-0081-2. View

Keefe D, Brealey J, Goland G, Cummins A . Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut. 2000; 47(5):632-7. PMC: 1728102. DOI: 10.1136/gut.47.5.632. View

Wardill H, Van Sebille Y, Mander K, Gibson R, Logan R, Bowen J . Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities: an emerging hypothesis for neuropathy and gastrointestinal toxicity. Cancer Treat Rev. 2014; 41(2):122-8. DOI: 10.1016/j.ctrv.2014.11.005. View

Kelly D, Campbell J, King T, Grant G, Jansson E, Coutts A . Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol. 2003; 5(1):104-12. DOI: 10.1038/ni1018. View

Medzhitov R, Preston-Hurlburt P, Janeway Jr C . A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997; 388(6640):394-7. DOI: 10.1038/41131. View

Lemaitre B, Nicolas E, Michaut L, Reichhart J, Hoffmann J . The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell. 1996; 86(6):973-83. DOI: 10.1016/s0092-8674(00)80172-5. View

Lee J, Mo J, Katakura K, Alkalay I, Rucker A, Liu Y . Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol. 2006; 8(12):1327-36. DOI: 10.1038/ncb1500. View

10.

Umesaki Y, Setoyama H . Structure of the intestinal flora responsible for development of the gut immune system in a rodent model. Microbes Infect. 2000; 2(11):1343-51. DOI: 10.1016/s1286-4579(00)01288-0. View

11.

Abreu M . Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol. 2010; 10(2):131-44. DOI: 10.1038/nri2707. View

12.

Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R . Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004; 118(2):229-41. DOI: 10.1016/j.cell.2004.07.002. View

13.

Logan R, Stringer A, Bowen J, Gibson R, Sonis S, Keefe D . Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther. 2008; 7(7):1139-45. DOI: 10.4161/cbt.7.7.6207. View

14.

Logan R, Gibson R, Bowen J, Stringer A, Sonis S, Keefe D . Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol. 2007; 62(1):33-41. DOI: 10.1007/s00280-007-0570-0. View

15.

Gibson R, Keefe D, Thompson F, Clarke J, Goland G, Cummins A . Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci. 2002; 47(12):2751-7. DOI: 10.1023/a:1021061306913. View

16.

Cata J, Weng H, Dougherty P . Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy. Brain Res. 2008; 1230:91-8. PMC: 2630495. DOI: 10.1016/j.brainres.2008.07.022. View

17.

Cata J, Weng H, Dougherty P . The effects of thalidomide and minocycline on taxol-induced hyperalgesia in rats. Brain Res. 2008; 1229:100-10. PMC: 2577234. DOI: 10.1016/j.brainres.2008.07.001. View

18.

Boogerd W, Ten Bokkel Huinink W, Dalesio O, Hoppenbrouwers W, van der Sande J . Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. J Neurooncol. 1990; 9(3):255-63. DOI: 10.1007/BF02341156. View

19.

Dougherty P, Cata J, Cordella J, Burton A, Weng H . Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain. 2004; 109(1-2):132-42. DOI: 10.1016/j.pain.2004.01.021. View

20.

Connelly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G . Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol. 1996; 62(2):166-8. DOI: 10.1006/gyno.1996.0210. View